Compass Therapeutics (CMPX) 8-K Summary
Compass Therapeutics, Inc. filed this Form 8-K on November 5, 2025, announcing financial results.
Key Event: Release of financial results for the quarter and nine months ended September 30, 2025.
Financial Details: Specific financial metrics are not included in the 8-K body; investors must refer to Exhibit 99.1 (the furnished press release) for detailed performance data.
Registrant Status: CMPX is classified as an Emerging Growth Company.
Filing Personnel: Signed by Neil Lerner, Chief Accounting Officer.
Co